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Introduction: The Canadian Organ Replacement Register (CORR) is the only Canadian information system on
kidney and extra-kidney organ failure and transplantation in Canada. CORR’s mandate is to record and analyze the
level of activity and outcomes of vital organ transplantation and treatment of end stage kidney disease using
dialysis, either hemodialysis or peritoneal dialysis, activities across Canada. The Canadian Organ Replacement
Register was officially launched in 1987, and it included transplantation of extra-renal vital organs (liver, heart, lung,
pancreas, bowel), in addition to renal transplantation and replacement therapy, with new financial support from the
provinces.
Objective: This manuscript describes the process of data acquisition and reporting, focusing on the patients
with end stage kidney disease on dialysis, with data reported from the 2014 CORR Annual Data Report and the
Center-Specific Reports on Clinical Measures.
Methods: CORR is currently housed in the Canadian Institute for Health Information and collects data from hospital
dialysis programs, regional transplant programs, organ procurement organizations and kidney dialysis services
offered at independent health facilities. Data on patients is collected by completion of survey forms for each
patient at the start of dialysis or receiving a transplant, using the Initial Registration form, and yearly follow up
forms, which collects data on the status of the patient as of October 31st.
Results: The incident rate per million population (RPMP) has remained stable with the exception of the 65+ age
group with has experience a modest decrease since 2001. However, there has been an increasing prevalence of
ESKD diagnoses, with the highest rate per million population (RPMP) amongst the age group 65+ years. This is
likely attributed to gradual improving patient survival. Between 2003 and 2012, nearly 90% of dialysis patients
younger than <18 and 26% of patients 75+ years survived for at least five years.
Conclusion: As the number of people treated for end-stage organ failure grows, so does the importance of
understanding their treatment and outcomes. In 2014, CORR continues to evolve and support the important
information need to advance ESRD research and clinical practice.
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Introduction: Le Registre canadien des insuffisances et des transplantations d’organes (RCITO) est le seul
réseau d’information sur l’insuffisance rénale et extrarénale et la transplantation au Canada. Le mandat du
RCITO est de rapporter et d’analyser le niveau d’activité et les résultats des transplantations d’organes
vitaux, de même que le traitement de l’insuffisance rénale terminale (IRT) par la dialyse, sous forme
d’hémodialyse ou de dialyse péritonéale, au Canada. Le registre a officiellement été lancé en 1987, et il
comprenait la transplantation d’organes vitaux extrarénaux (foie, cœur, poumon, pancréas, intestin), en plus
de la transplantation rénale et de la thérapie de remplacement rénal, grâce à un financement nouveau des
provinces.
Objectifs: Le présent manuscrit décrit le processus d’acquisition et de communication des données sur les
patients au stade d’insuffisance rénale terminale qui ont une thérapie de remplacement rénal, et des
données tirées du rapport annuel de 2014 du RCITO et de rapports concernant les centres au sujet des
mesures cliniques.
Méthodes: Le RCITO est actuellement hébergé par l’Institut canadien d’information sur la santé et recueille
des données au sujet des programmes de dialyse en milieu hospitalier, des programmes régionaux de
transplantation, des services de prélèvement d’organes et des services de dialyse rénale offerts dans des
établissements de santé indépendants. Les données sur les patients sont recueillies par le truchement d’un
sondage mené auprès de chaque patient au début de la dialyse ou avant une transplantation, grâce au
formulaire d’enregistrement et aux formulaires de suivi annuels, qui recueillent des données sur le statut du
patient en date du 31 Octobre.
Résultats: Le taux d’incidence par million de population est demeuré stable, à l’exception de la tranche
d’âge des 65 ans et plus, qui a subi une faible diminution depuis 2001. Toutefois, il y a eu prévalence
accrue des diagnostics d’IRT, avec le taux le plus élevé par million de population chez les 65 ans et plus.
Ceci est probablement attribuable à l’amélioration graduelle de la survie des patients. Entre 2003 et 2012,
près de 90% des patients en dialyse âgés de moins de 18 ans et 26% des patients de plus de 75 ans ont
survécu pendant au moins 5 ans.
Conclusion: L’importance de comprendre les traitements appropriés et les résultats croît à mesure
qu’augmente le nombre de personnes traitées pour insuffisance d’organe. En 2014, le RCITO continue
d’évoluer et de soutenir les besoins considérables en information afin de faire avancer la recherche et la
pratique clinique en IRT.What was known before
There is a growing interest in using chronic disease regis-
tries; these data sources provide important information for
policy and effective health system management, as well as
for research.
What this adds
The evolution of the Canadian Organ Replacement Regis-
ter over its 40-year history has made it a valuable resource
for management of kidney and extra-kidney organ failure
and transplantation in Canada. Here, we describe the
methodology for data acquisition and distribution and
provide specific examples of the rich data that is avai-
lable in the Canadian Organ Replacement Register, with
a particular emphasis on end-stage kidney disease.
Background
The Canadian Organ Replacement Register (CORR) is
the only Canadian information system on kidney and
extra-kidney organ failure and transplantation in Canada.CORR’s mandate is to record and analyze the level of
activity and outcomes of vital organ transplantation and
treatment of end stage kidney disease using dialysis, either
hemodialysis (HD) or peritoneal dialysis (PD), activities
across Canada. CORR provides data and information
on vital organ replacement therapy, with the goal of en-
hancing treatment, research and patient care. Strategic
advice for CORR is provided by the CORR Board of
Directors, which is comprised of representatives from
the Canadian Society for Nephrology, Canadian Society
for Transplantation, Canadian Blood Services, Kidney
Foundation of Canada, and other allied kidney health
professionals. Major stakeholders include the Canadian
Society of Transplantation, the Canadian Society of
Nephrology, the Canadian Transplant Association,
Health Canada, The Kidney Foundation of Canada,
and the Canadian Association of Nephrology Nurses
and Technologists.
The Canadian Institute for Health Information (CIHI)
manages CORR operations, data collection, dissemination
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and maintenance of comprehensive and integrated health
information that enables sound policy and effective health
system management that improve health and health care.
Although voluntary, CORR provides a comprehensive na-
tional perspective on the treatment of end organ failure in
Canada. For example, CORR captures over 98% of all solid
organ transplant recipients and 93% of renal dialysis pa-
tients in Canada [1].
History of CORR
The over 40-year history of CORR can be broken into
three distinct phases. In the late 1960s, Dr. Arthur Shimizu
of McMaster University in Hamilton, Ontario began
collecting statistics on dialysis in Ontario that would
become the first Renal Failure Register. This project
was so successful that it was expanded to include all of
Canada by 1972, with the support of the Kidney Founda-
tion of Canada and the Canadian Society of Nephrology.
In 1973, the Register was transferred to Statistics Canada,
in collaboration with the Kidney Foundation of Canada.
The first report was published in 1974. In the mid-
seventies, the Register was re-named to the “Canadian
Renal Failure Register”, and more detailed annual re-
ports were prepared.
In 1978, the register was decommissioned due to bud-
getary constraints. The register was re-started again in
September 1981 under a new partnership among the Kid-
ney Foundation of Canada, National Health and Welfare
and Statistics Canada. Dr. Gerald Posen served as the pro-
ject’s Medical Director, receiving guidance from the
Canadian Society of Nephrology. This group’s first re-
port was produced in 1981 and was also made available
in French.
In 1987, the Register expanded, under the driving force
of Dr. John Jeffrey, to include transplantation of other vital
organs (liver, heart, lung, pancreas, bowel), in addition to
renal transplantation and replacement therapy, with new
financial support from the provinces. To reflect this
change, the register was renamed the “Canadian Organ
Replacement Register”. Data collection on non-renal
transplant patients began formally on January 1, 1989,
although some data were collected on patients trans-
planted prior to this date. In 1995, CORR was trans-
ferred to the Canadian Institute for Health Information
(CIHI), which maintains various pan-Canadian regis-
tries and data holdings.
CORR operation
The Canadian Institute for Health Information (CIHI)
manages CORR operations, data and reporting. The
current CORR team at CIHI consists of two quality as-
surance assistants, one data entry staff, three analysts and
a program lead. The team manages all data submissionand operational activities, creates analytical products,
performs quality assurance, and processes data requests
from researchers and other organizations. Other CIHI
departments providing support to CORR include in-
formation and technology services, publications, trans-
lation, communications, privacy and legal services, and
administration. CIHI receives the majority of its fun-
ding, based on a proportional model, from the pro-
vincial/territorial ministries of health and the federal
government.
Subject to its privacy policy, CIHI makes its data avail-
able to enable responsive and effective health-system
planning and decision-making. Researchers can request
data from CORR via CIHI’s custom data request process.
Data can be retrieved at an aggregate or record level. A
formal Data Request form, along with a Non-Disclosure/
Confidentiality Agreement (NDCA) are completed by
the data requestor and submitted to CORR. The CORR
team then corresponds with the data requestor and pre-
pares detailed specifications for the request. The CORR
team processes the request according to the final specifi-
cations, and makes arrangement with the requestor to
ensure secure delivery of the data. For more information
on CIHI’s custom data request process, please see CIHI’s
Access Data page. Researchers using data from the
CORR have published in top nephrology journal and al-
tered clinical practice [2-5].
Data sources
CORR’s target population includes all patients that
received extra-renal organ transplant since January 1,
1988, and all chronic kidney failure patients who initi-
ated renal replacement therapy (RRT) with either dialy-
sis or transplantation as of January 1, 1981. CORR does
not contain information on patients who have been
determined to have acute kidney failure who require
dialysis; patients with chronic kidney disease not on
dialysis; recipients of tissue transplants or bone marrow
transplants; patients who were listed for but did not re-
ceive a vital organ transplant; and potential organ do-
nors (that is, deceased donors who met the criteria for
donation but from whom no organs were used for trans-
plantation). In June 2010, the CORR Board, in partner-
ship with CIHI, initiated data collection on all newly
referred ESKD patients at 16 of 18 adult kidney trans-
plant centres across Canada. This objectives of the
“Access to Kidney Transplantation Feasibility Project
are to gain insights into the types of ESKD patients
being referred for kidney transplant, assess the time-
liness and effectiveness of wait-listing practices, and
track the outcomes of patients wait-listed for deceased
donor kidney transplantation. Over 7,000 patients have
been recruited into this study with expected reporting
of outcomes in 2015.
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regional transplant programs, organ procurement orga-
nizations (OPOs) and kidney dialysis services offered at
independent health facilities. CORR receives data in a
privacy-secure manner on standardized paper forms or
spreadsheets. In 2011, CORR also began receiving dialy-
sis data through electronic submissions using a recently
implemented standard file format. Currently, approxi-
mately 40% of all ESKD data in CORR are submitted
electronically using the new standard file format. Data
submission to CORR will be fully electronic as of the
2015 data year, either using the standard file format or
via a new web-based data entry tool. The Ontario Renal
Network was the first organization to submit data elec-
tronically using the new standard. All data is processed
at CIHI’s Toronto office. Data within the database is
collected and reported on a calendar-year basis (January 1
to December 31), as is the practice in other interna-
tional registries reporting on end-stage organ failure.
Consistent with other national end-stage organ failure
registries, CORR’s annual data report includes data from
the latest calendar year for which CORR has received
complete data.
This paper will describe the process of data acquisition
and reporting in CORR, with a specific focus on patients
with end stage kidney disease (ESKD) with data reported
from the 2014 CORR Annual Data Report [6] and the
Center-Specific Reports on Clinical Measures describing
prevalent dialysis patients for whom CORR had received
follow-up data. A second paper, in this series, will report
on the patients with organ transplants [7].
Data collection
Six forms are used to collect data on the incidence, preva-
lence, and outcome of all patients (adults and pediatric)
with ESKD requiring dialysis, either HD or PD. These
forms include: an Initial Registration, a Change of Status,
a Follow-Up (Hemodialysis and Peritoneal Dialysis), and
a Facility Profile form (Hemodialysis and Peritoneal
Dialysis) (forms included in Additional file 1: Appendix 1
Form 1-6).
Data on ESKD patients is collected by completion of
survey forms (mentioned above) for each patient at the
start of dialysis, using the Initial Registration form, and a
yearly follow up forms, which collects data on the status
of the patient as of October 31st. CORR’s data is patient-
oriented; when a patient is first entered into CORR, a
patient identification number is assigned that will re-
main with the patient throughout their course of treat-
ment. This allows for a kidney transplant record, for
example, to be added to existing patient records if the
patient received dialysis treatments prior to the trans-
plant. Patients are then tracked from their first treatment
for end-stage kidney disease (dialysis or transplantation)to their death, unless they become lost to follow-up or re-
gain renal function. For the purposes of recording con-
tinuity of care, CORR captures out-of-country transfers
when informed by reporting facilities.
The Initial Registration form is completed for all newly
registered ESKD patients initiating dialysis. Dialysis nur-
ses and nephrologists (and at some sites unit clerks) do-
cument patient demographic information, the primary
kidney diagnosis, and existing comorbid conditions at
the time of initial dialysis, in a standardized CORR form
within 3 months of starting dialysis. The Change of Status
form is completed for existing patients as treatment
changes occur during the year. The Follow-Up form
is completed for all living patients on dialysis patients
on October 31st of each year and includes laboratory
indices, vascular access and information by modality.
The Facility Profile is completed by each facility that
provides dialysis to ESKD patients on December 31st
of each year.
CORR publishes an Annual Data Report that provides
the latest data on dialysis, organ transplants, waiting list
and donors. The latest report issued in 2014, reports on
data from 2003–2012 and is available on CIHI’s website
(http://www.cihi.ca). The Center-Specific Reports on Cli-
nical Measures reports are new series of reports, re-
leased in 2014, designed for dialysis centres and derived
primarily from the clinical measures captured in the an-
nual follow-up survey. This includes patient demograph-
ics, comorbidities, and laboratory and clinic indicator
comparisons for the center, the province and Canada.
Data quality
Assessing the quality of CORR data is recognized as crit-
ical to ensure continued use of its data as a clinical and
research tool. A validation study was conducted to assess
the quality of coding of demographics, primary renal dis-
ease and comorbid conditions of patients at the start of
chronic dialysis treatment compared with the patient’s
medical chart (reference standard) [8]. Table 1 lists the
sensitivity and specificity for each comorbidity used in
CORR. We conducted a sensitivity analysis to examine if
the risk of mortality would be significantly different de-
pending on the data source used. Despite some coding
issues in CORR, the direction of hazard ratios for mor-
tality were similar whether these were calculated using
the CORR data or study data obtained from chart ab-
straction. However, the magnitude for the hazard ratio
for mortality changed for several of the risk factors.
Incident patient population
In 2012, there were 5,431 newly diagnosed patients
with ESKD reported to CORR, almost double the num-
ber reported in 1993. The highest rate per million po-
pulation (RPMP) continues to be among those age 75
Table 1 Sensitivity and specificity of comorbid conditions





Angina 0.64 (0.56, 0.73) 0.91 (0.90, 0.92)
Myocardial infarction 0.62 (0.53, 0.70) 0.94 (0.91, 0.96)
Coronary artery bypass
grafts/angioplasty
0.69 (0.61, 0.77) 0.97 (0.95, 0.99)
Recent history of
pulmonary edema
0.62 (0.56, 0.68) 0.93 (0.91, 0.96)
Cerebrovascular disease 0.59 (0.48, 0.69) 0.96 (0.94, 0.98)
Peripheral vascular
disease
0.47 (0.38, 0.55) 0.96 (0.95, 0.97)
Diabetes 0.86 (0.82, 0.90) 0.97 (0.96, 0.99)
Malignancy existing prior
to first treatment
0.66 (0.57, 0.75) 0.99 (0.98, 0.99)
Chronic obstructive lung
disease
0.60 (0.49, 0.70) 0.96 (0.94, 0.98)
Receiving medication for
hypertension
0.89 (0.87, 0.92) 0.52 (0.39, 0.64)
Other serious illness 0.22 (0.14, 0.30) 0.93 (0.92, 0.94)
Current smoker 0.54 (0.46, 0.62) 0.95 (0.93, 0.97)
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dence rates among older age groups has slowly declined.
Provincially, in 2012, the highest incidence occurred in
Newfoundland and Labrador (212.6 RPMP) and Manitoba
(222.6 RPMP) (Figure 2). Of the incident patients, 78.5%
received institutional HD as their initial treatment, 11.9%
Continuous Ambulatory Peritoneal Dialysis (CAPD), 5.9%
Automated Peritoneal Dialysis (APD), 0.4% Home Hemo-
dialysis (HH) and 3.4% as preemptive transplant. The pro-
portion of patients receiving HD and PD as the initialFigure 1 Incident ESKD patients, age-specific rate per million populatform of treatment has been stable since 2003. The use
of preemptive transplants increased over time, from
119 in 2003 to 184 in 2012. Age of incidence also influ-
ences the initial treatment. In 2012, 72% of incidence
patients age 20 to 44 started with HD, while among those
age 65 and older, the proportion was 84%. Pre-emptive
transplant as an initial treatment was highest among
younger age groups and declined with patient age.
When dialysis was used to treat incident patients in
2012, all provinces used HD the majority of the time,
with Newfoundland and Labrador having the highest
proportion of HD (94%), followed by Saskatchewan (87%).
The highest proportion of patients treated by continuous
ambulatory peritoneal dialysis (CAPD) was observed in
New Brunswick (20%). More than half (53%) of the newly
diagnosed ESKD patients were 65 years and older and
36% were between the age of 45 and 64 years.
Select characteristics of the incident HD and PD popu-
lation, from 2003–2012, are described in Table 2. In 2012,
the average age of incident HD patients was 65.0, and the
average age of PD patients was 62.1. Patients 65 or older
accounted for 56% of incident HD patients, while males
accounted for 63%.
A patient who starts dialysis less than 90 days after
first seeing a nephrologist is considered a late referral
patient. This characteristic is considered a measure of
how well the early stages of kidney disease are managed.
An earlier referral allows for better management of the
disease and has been shown to influence patient survival
[9-11]. In 2012, 27% of incident patients were late refer-
rals, down from 37% in 2003. This improvement can be
seen in all provinces. Late referral is significantly lower
among patients starting PD compared to HD, and both
modalities have shared a decline in late referrals (Table 2).ion, Canada, 1993 to 2012.
Figure 2 Incident ESKD patients, rate per million population by Province, Canada, 2012. *Under-reporting of incident ESKD cases from
Quebec was estimated to be approximately 560 cases in 2012. This under-reporting is due to administrative issues that have temporarily halted
data submission to CORR.
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in many other countries, there has been a trend for pa-
tients to start dialysis at a higher level of kidney function
or estimated glomerular filtration rate (eGFR) [2,12].A
randomized controlled trial identified that starting atTable 2 Adult incident hemodialysis and peritoneal dialysis p
Variable 2003 2004 2005 20
HD Mean Age (Years) 65.0 65.0 65.2 65
Age 65+ (%) 58.2 57.8 59.4 57
Male (%) 60.3 59.6 60.2 59
Diabetes (%)£ 44.5 45.0 46.0 47
Mean Comorbidity Index† 2.1 2.0 2.0 2.
Mean BMI 27.0 27.4 27.5 27
Mean eGFR‡ 9.8 9.7 10.1 10
Late Referral (%)§ 41.7 41.3 39.5 37
PD Mean Age (Years) 60.5 60.3 61.3 60
Age 65+ (%) 45.0 42.6 47.0 44
Male (%) 59.8 56.7 60.3 55
Diabetes (%)£ 41.7 43.4 45.1 43
Mean Comorbidity Index† 1.5 1.3 1.4 1.
Mean BMI 26.4 26.5 26.8 27
Mean eGFR‡ 9.8 9.9 10.1 10
Late Referral (%)§ 16.2 15.8 11.4 12
Notes: *Under-reporting of incident ESKD cases from Quebec was estimated to be a
†This is an adaptation of the Charlson Index for ESRD patients; it assigns each of th
‡Estimated glomerular filtration rate as determined by the Modification of Diet in R
§Patients who first see a nephrologist less than 90 days before starting dialysis.
£Includes cases where diabetes was reported as the primary reason for dialysis or a
HD: Hemodialysis; PD: Peritoneal dialysis; BMI: Body mass index.higher levels of eGFR (ie > 6 ml/min) without symptoms
attributed to kidney failure was not associated with any
improvement in clinical outcome [13,14]. Among early
referral patients, that is patients who were treated by a
nephrologist at least 3 months prior to initiating dialysis,atients, selected characteristics, Canada, 2003 to 2012
06 2007 2008 2009 2010 2011* 2012*
.1 65.0 65.3 65.4 65.4 65.3 65.0
.9 57.7 57.8 58.1 57.0 57.5 56.3
.6 61.9 61.0 59.9 61.1 62.1 63.2
.7 49.3 48.5 49.8 51.2 53.5 53.6
0 2.1 2.1 2.1 2.1 2.3 2.1
.7 27.6 28.2 28.2 28.3 28.3 28.8
.2 10.2 10.4 10.6 10.6 10.5 10.5
.7 36.0 35.7 35.9 34.8 33.6 31.4
.6 61.1 60.8 61.9 61.7 60.9 62.1
.0 45.7 44.6 45.7 46.1 43.2 46.1
.0 58.5 57.4 57.6 59.4 60.3 60.3
.2 43.7 42.7 44.5 47.0 45.4 51.6
2 1.3 1.1 1.1 1.3 1.2 1.2
.2 27.1 27.5 28.0 27.5 27.3 27.9
.0 10.5 10.7 10.7 10.9 10.1 10.0
.2 11.3 10.4 10.1 8.6 9.1 6.7
pproximately 170 cases in 2011 and 560 cases in 2012.
e 14 comorbid conditions a value of 1 to 10.
enal Disease (MDRD) formula (mL/min/1.73 m2).
s a co-morbidity.
Figure 3 Prevalent ESKD patients, age-specific rate per million population, Canada, 1993 to 2012.
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10.5 ml/min/m2 declined from 40.3% in 2010 to 37.1%
in 2012. The mean eGFR for patients starting HD and
PD has been relatively similar over time (Table 2).
BC = British Columbia; YT = Yukon; Alta = Alberta;
NWT =North West Territories; Nun = Nunavut Sask =
Saskatchewan; Man =Manitoba; Ont = Ontario; Que =
Quebec; N.B New Brunswick; NS = Nova Scotia; NL =
Newfoundland.
Prevalent patient population
For CORR, prevalence is defined as the number of patients
who are alive and receiving RRT (dialysis or transplant)Figure 4 Unadjusted three month and one, three and five-year surv
2012 (percentage).for ESKD on December 31 of a given year. As of De-
cember 31, 2012, there were 41,252 people in Canada
being treated for ESKD, with 58% (23,814) on dialysis
and 42% (17,438) living with a functioning kidney trans-
plant. Since 1993, the prevalence rate for patients being
treated by dialysis has increased nearly 141%, from
283.2 RPMP to 682.7 RPMP. Figure 3 shows the rates of
prevalent ESKD patients by age group. Over the 20-year
period, prevalence rates increased in all age groups except
among those ages 0 to 19 years. Similar to incident rates,
prevalence rates in 2012 were highest in Newfoundland
and Labrador and Manitoba (1,576.1and 1,559.6 RPMP).
Although the incident rate among those over age 75 yearsival rates*. In Dialysis Patients, by Age Group, Canada 2003 to
Table 3 Demographics and diagnoses:* follow up
hemodialysis and peritoneal patients**, Canada 2012
Variable Hemodialysis Peritoneal
dialysis
Total Patients N 14,632 3,128
Age Mean (SD) 64.9 (15.4) 62.4 (14.9)
≥75 % 31.3 22.9
Male % 58.7 58.5
Race
Caucasian % 63.8 61.2
Black % 5.8 4.9
Asian % 7.4 12.4
Aboriginal % 6.8 6.1
Other % 10.7 10.1
Unknown % 5.5 5.4
BMI Mean 28.6 27.6
<18.5: Underweight % 3.2 2.7
18.5–24.9: Normal % 28.2 31.6
25.0–29.9: Overweight % 26.2 30.6
≥30: Obese % 29.5 24.6
Unknown % 12.9 10.4
Primary Cause of ESKD
Glomerulonephritis % 13.3 17.2
Diabetes % 35.8 32.6
Renal Vascular Disease % 16.5 16.8
Polycystic Kidney Disease % 4.3 6.1
Pyelonephritis % 4.4 3.2
Other % 12.0 11.2
Unknown % 13.8 12.9
Comorbidity Index† Mean 1.9 1.4
Diabetes‡ % 47.4 42.1
Submodality -
CAPD % - 27.5
APD % - 72.5
Notes: *Data in this table is collected at the time of initial dialysis treatment
for chronic renal failure.
†This is an adaptation of the Charlson Index for ESRD patients; it assigns each
of the 14 comorbid conditions a value of 1 to 10.
‡Includes cases where diabetes was reported as the primary reason for dialysis
or as a co-morbidity.
**Number of follow up patients differs from the number of prevalent patients
reported in the CORR Annual Report (75% reported data and excludes
patients < 18 years of age).
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creasing suggesting an improved survival in this age
group. Hemodialysis provided in an institutional setting
was the most common form of RRT across the country
(45%), followed by transplant (42%). Among patients
receiving dialysis 82% received HD and the remaining
18% were on PD. Among those receiving PD, 72% were
using APD and the remaining on CAPD. Between 2003
and 2012, the prevalence rate of patients with diabetes
as a primary diagnosis increased by 41%.
Patient outcomes
The factors associated with the survival of patients re-
ceiving dialysis treatment are well documented [5].
Long-term survival rates have been gradually improv-
ing. In general, both age and primary diagnosis affect
survival of dialysis patients. Nearly 90% of dialysis pa-
tients younger than 18 survive for five years, while 26%
of patients older than 75 survive for five years (Figure 4).
Patients with renal vascular disease, drug-induced renal
failure and diabetes have the lowest five-year survival
rates, at 37%, 39% and 41%, respectively. The longest
five-year survival rate is seen among patients with a pri-
mary diagnosis of polycystic kidney disease (75%) and
glomerulonephritis (65%). Patients were censored at kid-
ney transplant, lost to follow-up, left the country, or re-
covered kidney function. Data on survival outcomes by
modality are provided in the CORR Annual Report [6].
Center-specific report on clinical measures
In 2014, CORR developed a unique quality assessment
report, the Center-Specific Report on Clinical Measures,
which describes, at the facility level, data on patients in-
cluded in the annual follow up survey as of October 31st
each year and compares facility level data to provincial
and national level data. This report only includes faci-
lities that submitted follow-up data (about 75% of pre-
valent patients) and excludes patients < 18 years of age.
The report includes the most recent 3-year (2010 to
2012) period and compares outcomes of the individual
unit to that of the province and that of Canada. The
Canadian data, from this report, is described below and
in Tables 3, 4 and 5.
In 2012, the mean age of patients on HD was 64.9 years
and patients on PD were almost 2.5 years younger
(Table 3). In 2012, diabetic nephropathy accounted for
the largest proportion of all prevalent patients (35%),
followed by renal vascular disease (17%), and glomerulo-
nephritis (13%). Overall, patients with diabetes (cause of
ESKD or comorbidity) accounted for 47% of HD and
42% of PD patients (Table 3).
Tables 4 presents the data collected in the yearly follow
up form for patients on HD and PD in 2012 and reported
in the Center-Specific Report on Clinical Measures. Thedata are presented to highlight the proportion of patients
in different ranges of indicators, with the proportion in
the recommended range highlighted. The recommended
ranges are taken from the Canadian Society of Nephrology
guidelines or consensus statements pertaining to the care
of patients on dialysis [14-17]. With the exception of
serum phosphate, over 50% of HD patients fell within
Table 4 Clinical ranges:* follow-up hemodialysis and
peritoneal dialysis patients, per Canada 2012
Variable Hemodialysis Peritoneal
dialysis
Dialysis Adequacy N 11,380 1,759
Urea Reduction Ratio ≥65 % 86.7 -
Kt/V,† <1.2 % 23.4 8.7
Kt/V 1.2–2.0 % 52.1** 14.5
Kt/V >2.0 % 2.4 33.0
Test Not Done % 22.2 43.8
Hemoglobin N 14,584 3,106
<95 g/L % 11.6 11.9
95–115 g/L % 55.3** 54.1**
>115 g/L % 32.8 33.2
Test Not Done % 0.3 0.7
Transferrin Saturation N 13,827 2,829
<20% % 25.9 20.2
20%–50% % 64.2** 66.0**
>50% % 4.4 4.3
Test Not Done % 5.5 9.6
Ferritin N 13,831 2,870
<100 ng/mL % 13.1 18.6
100–800 ng/mL % 64.8** 63.9**
>800 ng/mL % 16.6 9.2
Test Not Done % 5.5 8.2
Target for Hgb, TSAT and FTN % 26.3 27.1
Erythropoietin % 89.1 73.6
Use Iron Administration
No Iron % 31.4 50.8
Oral % 12.0 43.0
IV % 53.4 4.6
Oral and IV % 2.9 1.0
Unknown/Other % 0.4 0.6
Calcium N 13,936 2,966
<2.1 mmol/L % 11.5 6.5
2.1–2.54 mmol/L % 69.1** 67.6**
>2.54 mmol/L % 14.7 20.8
Test Not Done % 4.8 5.2
Phosphate N 14,570 3,099
<0.80 mmol/L % 1.9 0.5
0.80–1.45 mmol/L % 36.8** 33.9**
>1.45 mmol/L % 60.9 64.6
Test Not Done % 0.4 0.9
Parathormone N 14,268 2,965
<10.6 pmol/L % 15.4 14.4
10.6–53.0 pmol/L % 53.6** 58.2**
Table 4 Clinical ranges:* follow-up hemodialysis and
peritoneal dialysis patients, per Canada 2012 (Continued)
>53.0 pmol/L % 28.6 22.3
Test Not Done % 2.5 5.2
Target for Ca, P and PTH % 16.3 16.6
Albumin N 14,469 3,088
<35 g/L % 38.3 53.8
35-40 g/L % 44.3** 36.0**
>40 g/L % 16.2** 8.9**
Test Not Done % 1.1 1.3
HbA1c N 7,055 1,586
≤7% % 61.7 62.7
On Kidney Transplant Wait List % 21.7 34.9
5+ Treatments/Week % 4.4 -
15+ Hours/Week % 8.6 -
Notes: *The clinical measures reported in this table are from the annual
patient follow-up as of October 31.
**Rows may be considered approximate clinical targets.
†Kt/V is based on URR; For HD, Kt/V is an estimation, based on the urea
reduction ratio. For PD, the total weekly Kt/V (residual renal + PD) is reported.
For descriptive purposes, test values are divided into high, medium, and low.
Table 5 Descriptive statistics:* follow-up hemodialysis
and peritoneal dialysis patients, Canada 2012
Variable Hemodialysis Peritoneal
dialysis
Kt/V¥ N 11,380 1,759
Median (IQR) 1.3 (0.3) 2.1 (0.7)
Hemoglobin (g/L) N 14,584 3,106
Median (IQR)) 110.0 (6.0) 110.0 (7.0)
Transferrin Saturation (%) N 13,827 2,829
Median (IQR)) 25.0 (14.0) 27.0 (15.0)
Ferritin (ng/mL) N 13,831 2,870
Median (IQR) 389.0 (510.0) 253.0 (365.0)
Calcium† (mmol/L) N 13,936 2,966
Median (IQR) 2.3 (0.3) 2.4 (0.2)
Phosphate (mmol/L) N 14,570 3,099
Median (IQR) 1.6 (0.6) 1.6 (0.6)
Parathormone (pmol/L) N 14,268 2,965
Median (IQR) 32.0 (43.0) 29.8 (35.0)
Albumin‡ (g/L) N 14,469 3,088
Median (IQR)) 36.0 (6.0) 34 (6.5)
HbA1c (%) N 7,055 1,586
Median (IQR) 6.6 (2.0) 6.6 (1.9)
Note: *The clinical measures in this table are from the annual patient follow-
up as of October 31.
¥For HD, Kt/V is an estimation, based on the urea reduction ratio. For PD, the
total weekly Kt/V (residual renal + PD) is reported.
†Calcium is corrected for albumin level. Results with ionized calcium
are excluded.
‡Albumin reagent is unknown.
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Table 6 Vascular access use in Canada, 2010 to 2012
(percentage)
Variable 2010 2011 2012
Incident Patients*
Catheter‡ 77.2 80.9 81.1
AV Fistula 16.9 15.6 15.8
AV Graft 1.2 0.8 0.9
Unknown 4.7 2.6 2.1
Prevalent Patients†
Catheter‡ 50.3 50.8 51.5
AV Fistula 45.6 45.1 44.4
AV Graft 3.8 4.0 3.8
Unknown 0.3 0.1 0.3
Notes: *Incident Patients include new adult patients who initiated
hemodialysis in the year listed.
Incident access refers to access at the time of initial dialysis treatment.
†Prevalent Patients include adult patients for whom CORR received follow-up
data by October 31st in the year listed.
Prevalent access refers to the access at the time of follow-up (October 31st).
‡Includes both permanent and temporary catheters.
Catheter: Central venous catheter; AV fistula: Arteriovenous fistula; AV graft:
Arteriovenous graft.
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pared to HD, patients being treated with PD were less
likely to fall within the clinical ranges. Of note, patients re-
ceiving HD were less likely to be on the transplant waiting
list compared to patients on PD (21.7 and 34.9% respect-
ively). Table 5 presents descriptive statistics (mean or me-
dian) for select clinical variables in 2012.
Vascular access
Table 6 presents data on the vascular access being used
for HD patients between 2010 and 2012. Incident adult
patients starting HD, using a catheter, increased from
77% to 81%, fistula use had a small numerical decrease
from 17% to 16%, and AV graft use remained stable at
approximately 1% (Table 6). Prevalent vascular access
use is reported from the follow-up form. Among preva-
lent patients, the proportion of patients using a using
the various types of HD vascular accesses remained rela-
tively stable. Fistula use remains low compared to other
jurisdictions, used in only 44.4% of patients in 2012 [18].
Future directions of CORR
What started as a grass roots initiative in a single prov-
ince has grown into a pan-Canadian information system
that receives data from a diverse and changing group of
dialysis programs, hospitals, provincial and national in-
formation systems. As part of CIHI, CORR has been
able to work with this diverse group of stakeholders to
maintain and provide a picture of organ replacement
therapy in Canada for over 40 years. The Canadian Kid-
ney Knowledge Translation and Generation Network(CANN-NET) has been established in partnership with
the CSN (Canadian Society of Nephrology) and the KFOC
(Kidney Foundation of Canada) to link Canadian kidney
disease guideline producers, knowledge translation spe-
cialists and knowledge users to improve knowledge dis-
semination and care of patients with kidney disease.
CORR data is being used to track the effectiveness of
knowledge translation activity on process of care and
clinical outcomes for patients with ESKD and to assist
with identifying knowledge gaps in end stage kidney
disease. There is a process for ongoing review of data
elements, outcomes reporting and quality improvement
initiatives. As the number of people treated for end-
stage organ failure has grown, so has the importance
of understanding their treatment and outcomes. In
2014, CORR continues to evolve to support this impor-
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